Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Eisai Medical Research Inc. |
---|---|
Information provided by: | Eisai Medical Research Inc. |
ClinicalTrials.gov Identifier: | NCT00165841 |
This is a study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
Condition | Intervention | Phase |
---|---|---|
Gastroesophageal Reflux Disease |
Drug: Rabeprazole Sodium |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients With Symptomatic Gastroesophageal Reflux Disease |
Estimated Enrollment: | 340 |
Study Start Date: | October 2004 |
Study Completion Date: | June 2008 |
Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Quality Care Medical Center Inc. | |
Vista, California, United States |
Study Director: | Yufang Lu | Eisai Medical Research Inc. |
Study ID Numbers: | E3810-A001-203 |
Study First Received: | September 13, 2005 |
Last Updated: | July 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00165841 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Deglutition Disorders Esophageal Motility Disorders Digestive System Diseases Esophageal Disorder |
Gastrointestinal Diseases Esophageal Diseases Gastroesophageal Reflux Rabeprazole |
Molecular Mechanisms of Pharmacological Action Gastrointestinal Diseases Gastrointestinal Agents Enzyme Inhibitors Gastroesophageal Reflux Pharmacologic Actions Esophageal Motility Disorders |
Deglutition Disorders Digestive System Diseases Therapeutic Uses Anti-Ulcer Agents Esophageal Diseases Rabeprazole |